The EMA’s CHMP has recommended Ultomiris for marketing authorization in the EU for adult patients with NMOSD who are anti-aquaporin-4 Ab+
The opinion was based on the P-III trial (CHAMPION-NMOSD) evaluating Ultomiris in 58 patients across North America, the EU, Asia-Pacific & Japan. The trial met its 1EPs of time to first on-trial relapse as confirmed by an independent adjudication committee & showed zero relapses with a median treatment duration of 73wks. (relapse risk reduction 98.6%) & continuing through a median duration of 90wks.
The safety & tolerability were consistent with prior studies and real-world use with no new safety signals. The regulatory submissions for Ultomiris are under review with multiple health authorities, incl. in the US & Japan
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Tezspire (tezepelumab) Receives NICE Recommendation as an Add-On Treatment for Severe Uncontrolled Asthma
